Related Experiment Video
Updated: Mar 21, 2026
Ultrasound Based Assessment of Coronary Artery Flow and Coronary Flow Reserve Using the Pressure Overload Model in Mice
Published on: April 13, 2015
Elevated endocan concentration is associated with coronary slow flow
Ming-Fang Ye1, Zi-Wen Zhao1, Yu-Kun Luo1
1a Department of Cardiology , Union Hospital, Fujian Medical University, and Fujian Institute of Coronary Artery Disease , Fuzhou , P. R. China.
Insights
Serum endocan levels are higher in patients with coronary slow flow (CSF). Elevated endocan is linked to CSF presence and severity, suggesting it may be a useful biomarker for this condition.
Area of Science:
- Cardiology
- Biomarkers
- Vascular Biology
Background:
- Coronary slow flow (CSF) is a condition affecting coronary artery blood flow.
- The role of specific biomarkers in CSF is an area of ongoing research.
- Endocan, a proteoglycan, has been implicated in vascular inflammation.
Purpose of the Study:
- To investigate the association between serum endocan concentration and coronary slow flow (CSF).
- To determine if serum endocan levels can serve as a predictive biomarker for CSF.
- To explore the correlation between endocan levels and the severity of CSF.
Main Methods:
- Serum endocan concentration was measured using enzyme-linked immunosorbent assay (ELISA).
- Coronary slow flow (CSF) was diagnosed using the thrombolysis in myocardial infarction (TIMI) frame count (TFC) method.
- Statistical analyses, including multivariate logistic regression, were employed to assess associations.
Main Results:
- Serum endocan concentration was significantly higher in patients with CSF compared to controls (1.03 vs. 0.80 ng/mL, p=0.002).
- Higher serum endocan levels were independently associated with the presence of CSF (OR 1.774, p=0.028).
- Serum endocan concentration showed a positive correlation with mean-TIMI frame count (r=0.289, p=0.005) in CSF patients.
Conclusions:
- Serum endocan may be a valuable biomarker for predicting the presence and severity of coronary slow flow.
- Further research is warranted to explore therapeutic strategies targeting endocan to manage CSF progression.
- Down-regulating endocan could potentially be a future therapeutic approach for CSF.
Abstract:
We sought to assess whether serum endocan concentration is correlated with coronary slow flow (CSF). We measured serum endocan concentration in 93 patients with CSF and in 206 controls. Serum endocan concentration was measured by enzyme-linked immunosorbent assay (ELISA). The presence of CSF was assessed by thrombolysis in myocardial infarction (TIMI) frame count (TFC) method. We demonstrated that serum endocan concentration is significantly higher in CSF patients (n = 93) than that in controls (n = 206) (1.03 [range 0.63-1.33] vs. 0.80 [range 0.52-1.09] ng/mL, p = 0.002). Multivariate logistic regression analysis revealed that serum endocan concentration was independently associated with the presence of CSF (odds ratio 1.774, 95% confidence interval 1.064-2.958; p = 0.028). Serum endocan concentration was positively correlated with mean-TFC in CSF patients (r = 0.289, p = 0.005). These results revealed that endocan might be a useful biomarker for predicting the presence and severity of CSF. Therapeutic interventions by down-regulating endocan to delay the progressive process of CSF warrants further investigations.
Related Concept Videos
01:26Coronary Artery Disease II: Pathophysiology
01:30Acute Coronary Syndrome I: Introduction
01:30Coronary Artery Disease III: Clinical Manifestations
01:30Acute Coronary Syndrome III: Diagnostic Studies
01:30Coronary Artery Disease I: Introduction
01:19Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations